Jul. 14 at 5:10 PM
$PRAX is getting major analyst attention as expectations build around ulixacaltamide.
Piper Sandler reiterated its Overweight rating with a
$1,200 target, while Goldman Sachs initiated coverage with a Buy and a
$447 target. Goldman believes ulixacaltamide has a strong chance of approval by the January 2027 PDUFA date and sees potential for significant commercial opportunity.
Biotech remains a high-risk space, but approval milestones can quickly change the valuation story.
